• About
    • Our Team
    • Clinical Advisory Board
    • Board of Directors
  • Product
  • Investors & Partners
  • News
  • Contact

News

Zucara Therapeutics Announces Additional Funding from JDRF to Support ZT-01 Phase 2 Study

June 15, 2023 by zucaraadmin

– Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in

read more

Zucara Therapeutics Receives IND Clearance for Phase 2 Clinical Trial of ZT-01

April 19, 2023 by zucaraadmin

– First patient dosing expected in Q3 2023 – – ZONE study to assess ZT-01’s ability to prevent night-time hypoglycemia,

read more

Zucara Therapeutics’ Positive Proof-of-Concept Data Secures Continued Funding Ahead of Planned Phase 2 Clinical Trial of ZT-01

September 19, 2022 by zucaraadmin

– Achieves development milestones required to complete Series A financing – – Plans to file Phase 2 investigational new drug

read more

Zucara Therapeutics Reports Positive Results from Phase 1b Trial of ZT-01

June 22, 2022 by zucaraadmin

– Proof-of-Concept Trial Confirms ZT-01’s Mechanism of Action in Restoring Glucagon Release in Patients with Type 1 Diabetes – –

read more

Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01

May 2, 2022 by zucaraadmin

Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01 – Second grants from GlycoNet and

read more

Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01’s Ability to Restore Glucagon Release in Type 1 Diabetes

February 8, 2022 by zucaraadmin

Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01’s Ability to Restore Glucagon Release in Type 1 Diabetes – ZT-01

read more

Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01

July 28, 2021 by zucaraadmin

Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01 – Proof-of-Concept Trial to Evaluate the Effect of ZT-01

read more

Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01

May 26, 2021 by zucaraadmin

Zucara Therapeutics Successfully Completes Single and Multiple Ascending Dose Phase 1 Trial of ZT-01 Toronto, Canada, May 26, 2021 –

read more

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes

November 2, 2020 by zucaraadmin

Zucara Therapeutics Expands ZT-01 Development Program to Type 2 Diabetes – ZT-01 Development for T2D to be Supported by Nearly

read more

Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01

September 29, 2020 by zucaraadmin

Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 – Phase 1 Trial to Evaluate ZT-01 for the

read more
  • 1
  • 2
  • 3
  • 4
  • Next Page»

OUR PARTNERS





CATEGORIES

  • News

Copyright 2023 Zucara Therapeutics, all rights reserved.